Live
- Delhi HC pulls up Meta over its handling of TV Today Network's complaint
- Palestinian factions hold talks in Beijing, achieve positive progress: China
- Indian Oil posts 52 pc dip in Q4 net profit amid sharp rise in crude oil cost
- Yogi govt to set up cyber police stations in 57 districts after Lok Sabha polls
- Delhi HC restrains Ashneer Grover from creating third party rights in BharatPe shares
- SP Amit Bardar prepares for elections in Uravakonda
- Cong has only one identity, betrayer: PM Modi in Dharashiv
- Nifty sees profit booking after hitting fresh record high
- As BJP's defeat at the national level is guaranteed, Modi is misleading Indians with horrendous lies: CM Siddaramaiah
- Actress Subhashree Sahu's Bold Stand Against Cyberbullying: An Odia Web Series
Ranbaxy: US Interested In Pricing Data
Indian generic drugmaker Ranbaxy Laboratories Ltd stated that federal authorities in the United States
Mumbai: Indian generic drugmaker Ranbaxy Laboratories Ltd stated that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program.
The company, which has agreed to be acquired by rival Sun Pharmaceutical Industries Ltd, said it had received a civil investigative demand (CID) from the U.S. Department of Justice (DOJ) and that it would fully cooperate with the investigation.
"The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation," the company said in a statement. Last year, Ranbaxy pleaded guilty to felony charges related to drug safety and agreed to pay $500 million in civil and criminal fines under a settlement agreement with the DOJ.
